Crizotinib in Sarcomatous Malignancies Harboring ALK Fusion With a Definitive Partner(s): Response and Efficacy

Crizotinib in Sarcomatous Malignancies Harboring ALK Fusion With a Definitive Partner(s): Response and Efficacy

Sarcoma or sarcomatoid malignancies are a set of mesenchymal-origin malignancies with vast heterogeneity in clinical and molecular characteristics. Anaplastic lymphoma kinase (ALK) is a tyrosine kinase oncoprotein expressed by several tumors, including sarcomas. Crizotinib is an effective ALK inhibi...

Full description

Bibliographic Details
Main Authors: Jinchun Wu, Yongbin Hu, Omar Abdihamid, Gengwen Huang, Sheng Xiao, Bin Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Oncology
Subjects:
crizotinib
sarcoma
sarcomatoid malignancies
ALK fusions
definitive partner(s)
adverse events
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.684865/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.684865/full

Similar Items